Differentially Expressed Transcripts and Dysregulated Signaling Pathways and Networks in African American Breast Cancer

African Americans (AAs) have higher mortality rate from breast cancer than that of Caucasian Americans (CAs) even when socioeconomic factors are accounted for. To better understand the driving biological factors of this health disparity, we performed a comprehensive differential gene expression analysis, including subtype- and stage-specific analysis, using the breast cancer data in the Cancer Genome Atlas (TCGA). In total, 674 unique genes and other transcripts were found differentially expressed between these two populations. The numbers of differentially expressed genes between AA and CA patients increased in each stage of tumor progression: there were 26 in stage I, 161 in stage II, and 223 in stage III. Resistin, a gene that is linked to obesity, insulin resistance, and breast cancer, was expressed more than four times higher in AA tumors. An uncharacterized, long, non-coding RNA, LOC90784, was down-regulated in AA tumors, and its expression was inversely related to cancer stage and was the lowest in triple negative AA breast tumors. Network analysis showed increased expression of a majority of components in p53 and BRCA1 subnetworks in AA breast tumor samples, and members of the aurora B and polo-like kinase signaling pathways were also highly expressed. Higher gene expression diversity was observed in more advanced stage breast tumors suggesting increased genomic instability during tumor progression. Amplified resistin expression may indicate insulin-resistant type II diabetes and obesity are associated with AA breast cancer. Expression of LOC90784 may have a protective effect on breast cancer patients, and its loss, particularly in triple negative breast cancer, could be having detrimental effects. This work helps elucidate molecular mechanisms of breast cancer health disparity and identifies putative biomarkers and therapeutic targets such as resistin, and the aurora B and polo-like kinase signaling pathways for treating AA breast cancer patients.

[1]  Baocun Sun,et al.  BMP-6 promotes E-cadherin expression through repressing δEF1 in breast cancer cells , 2007, BMC Cancer.

[2]  Jill P. Mesirov,et al.  GSEA-P: a desktop application for Gene Set Enrichment Analysis , 2007, Bioinform..

[3]  Stephen S. Taylor,et al.  Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores , 2003, The Journal of cell biology.

[4]  R. Steinman,et al.  Treml4, an Ig Superfamily Member, Mediates Presentation of Several Antigens to T Cells In Vivo, Including Protective Immunity to HER2 Protein , 2012, The Journal of Immunology.

[5]  N. A. Temiz,et al.  APOBEC3B is an enzymatic source of mutation in breast cancer , 2013, Nature.

[6]  Jacob J. Kennedy,et al.  Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. , 2011, Cancer research.

[7]  Karen H. Vousden,et al.  p53 in health and disease , 2007, Nature Reviews Molecular Cell Biology.

[8]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[9]  Anne M. Bowcock,et al.  Identification of a RING protein that can interact in vivo with the BRCA1 gene product , 1996, Nature Genetics.

[10]  I. Andrulis,et al.  Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry , 2012, Clinical Cancer Research.

[11]  H. Katayama,et al.  Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. , 1998, Cancer research.

[12]  Y. Maehara,et al.  Aurora-B overexpression is correlated with aneuploidy and poor prognosis in non-small cell lung cancer. , 2013, Lung Cancer.

[13]  B. Wójcik,et al.  Breast carcinoma survival analysis for african american and white women in an equal‐access health care system , 1998, Cancer.

[14]  Charles M Perou,et al.  FOXA1 Expression in Breast Cancer—Correlation with Luminal Subtype A and Survival , 2007, Clinical Cancer Research.

[15]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[16]  Damian Szklarczyk,et al.  STRING v9.1: protein-protein interaction networks, with increased coverage and integration , 2012, Nucleic Acids Res..

[17]  E. Calle,et al.  Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms , 2004, Nature Reviews Cancer.

[18]  Dawn L Hershman,et al.  Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. , 2009, Journal of the National Cancer Institute.

[19]  M. Stephens,et al.  RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. , 2008, Genome research.

[20]  Z. Ling,et al.  Possible role of Pax-6 in promoting breast cancer cell proliferation and tumorigenesis. , 2011, BMB reports.

[21]  Emmanuel Barillot,et al.  Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. , 2013, Cancer research.

[22]  Chien‐An Sun,et al.  Adipocytokine resistin and breast cancer risk , 2010, Breast Cancer Research and Treatment.

[23]  S. Gapstur,et al.  Hormone receptor status of breast tumors in black, Hispanic, and non‐Hispanic white women: An analysis of 13,239 cases , 1996, Cancer.

[24]  Michał Jankowski,et al.  Microarray‐based survey of CpG islands identifies concurrent hyper‐ and hypomethylation patterns in tissues derived from patients with breast cancer , 2006, Genes, chromosomes & cancer.

[25]  O. Griffith,et al.  Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast Cancer , 2011, Molecular Cancer Research.

[26]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[27]  R. Cress,et al.  Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.

[28]  Kenneth H. Buetow,et al.  PID: the Pathway Interaction Database , 2008, Nucleic Acids Res..

[29]  Takashi Suzuki,et al.  BUB1 Immunolocalization in Breast Carcinoma: Its Nuclear Localization as a Potent Prognostic Factor of the Patients , 2013, Hormones and Cancer.

[30]  J. Hornaday,et al.  Cancer Facts & Figures 2004 , 2004 .

[31]  Robyn L Prueitt,et al.  Tumor immunobiological differences in prostate cancer between African-American and European-American men. , 2008, Cancer research.

[32]  Xuegong Zhang,et al.  DEGseq: an R package for identifying differentially expressed genes from RNA-seq data , 2010, Bioinform..

[33]  R. Stephens,et al.  Differences in the Tumor Microenvironment between African-American and European-American Breast Cancer Patients , 2009, PloS one.

[34]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[35]  G M Clark,et al.  Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. , 1994, Journal of the National Cancer Institute.

[36]  Martin R. Johnson,et al.  Differential expression of breast cancer-associated genes between stage- and age-matched tumor specimens from African- and Caucasian-American Women diagnosed with breast cancer , 2012, BMC Research Notes.

[37]  James J. Vincent,et al.  TARP: a nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  U. Moll,et al.  Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. , 1999, Cancer research.

[39]  M. Hou,et al.  Resistin expression in breast cancer tissue as a marker of prognosis and hormone therapy stratification. , 2012, Gynecologic oncology.

[40]  M. Gerstein,et al.  The Transcriptional Landscape of the Yeast Genome Defined by RNA Sequencing , 2008, Science.

[41]  Ana Kozomara,et al.  miRBase: integrating microRNA annotation and deep-sequencing data , 2010, Nucleic Acids Res..

[42]  J. Mattick,et al.  Non-coding RNA. , 2006, Human molecular genetics.

[43]  Ian O Ellis,et al.  Basal-like breast cancer: a critical review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[45]  Serban Nacu,et al.  Gene expression network analysis and applications to immunology , 2007, Bioinform..

[46]  ADAMTS15 metalloproteinase inhibits breast cancer cell migration , 2010, Breast Cancer Research.

[47]  A. Rosenberg,et al.  Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients , 2007, Cancer.

[48]  B. Deyarmin,et al.  Identification of differentially expressed genes in breast tumors from African American compared with Caucasian women , 2012, Cancer.

[49]  Howard Y. Chang,et al.  Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis , 2010, Nature.

[50]  K. Fiscella,et al.  Poverty or income inequality as predictor of mortality: longitudinal cohort study , 1997, BMJ.

[51]  Frank B. Hu,et al.  Abdominal Obesity and the Risk of All-Cause, Cardiovascular, and Cancer Mortality: Sixteen Years of Follow-Up in US Women , 2008, Circulation.

[52]  A. Chinnaiyan,et al.  The emergence of lncRNAs in cancer biology. , 2011, Cancer discovery.

[53]  L. Carey.  Directed therapy of subtypes of triple-negative breast cancer. , 2010, The oncologist.

[54]  A. Chambers,et al.  Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays , 2008, Breast Cancer Research.

[55]  R. Shiekhattar,et al.  Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. , 2003, Molecular cell.

[56]  Donald Berry,et al.  Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 , 2006, Breast Cancer Research.

[57]  R. Coffey,et al.  LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor , 2013, British Journal of Cancer.

[58]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[59]  E. Devilard,et al.  Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. , 2002, Human molecular genetics.

[60]  W. McCaskill-Stevens,et al.  p53 as a Marker of Prognosis in African-American Women with Breast Cancer , 2010, Annals of Surgical Oncology.

[61]  G. Colditz,et al.  African‐American ethnicity, socioeconomic status, and breast cancer survival , 2002, Cancer.

[62]  Stephen S. Taylor,et al.  Aurora-kinase inhibitors as anticancer agents , 2004, Nature Reviews Cancer.

[63]  M. Emmett,et al.  Characterization of the phosphoproteome in androgen-repressed human prostate cancer cells by Fourier transform ion cyclotron resonance mass spectrometry. , 2011, Journal of proteome research.

[64]  G. Colditz,et al.  Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  C. Ambrosone,et al.  Breast cancer in African-American women: differences in tumor biology from European-American women. , 2006, Cancer research.

[66]  P. Murdock,et al.  Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. , 2003, Biochemical and biophysical research communications.

[67]  M. Kool,et al.  Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. , 1999, Cancer research.

[68]  Joanna D. Holbrook,et al.  Resistin is expressed in human macrophages and directly regulated by PPARγ activators , 2003 .

[69]  Xu Wang,et al.  Epigenetic regulation of bone morphogenetic protein-6 gene expression in breast cancer cells , 2007, Journal of Steroid Biochemistry and Molecular Biology.

[70]  J. Graw.  Genetics of crystallins: cataract and beyond. , 2009, Experimental eye research.

[71]  H. Becher,et al.  Widening disparity in survival between white and African‐American patients with breast carcinoma treated in the U. S. Department of Defense Healthcare system , 2003, Cancer.

[72]  C. Sigel,et al.  Differential Gene Expression between African American and European American Colorectal Cancer Patients , 2011, PloS one.

[73]  R. Calderon-Margalit,et al.  Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: A critical review of the literature , 2004, International journal of cancer.

[74]  A. Nicolas,et al.  UDP-N-Acetyl-d-Galactosamine: Polypeptide N-Acetylgalactosaminyltransferase-6 as a New Immunohistochemical Breast Cancer Marker , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[75]  T. Lash,et al.  Triple-negative breast cancers are increased in black women regardless of age or body mass index , 2009, Breast Cancer Research.

[76]  M. Lazar,et al.  The hormone resistin links obesity to diabetes , 2001, Nature.

[77]  K. Siziopikou,et al.  p53 Expression in Triple Negative Breast Carcinomas: Evidence of Age-Related and Racial Differences , 2012 .

[78]  S. Vadaparampil,et al.  BRCA1/2 in high-risk African American women with breast cancer: providing genetic testing through various recruitment strategies. , 2008, Genetic testing.

[79]  R J DUBOS,et al.  Health and disease. , 1960, JAMA.

[80]  S. Ichinose,et al.  Mieap, a p53-Inducible Protein, Controls Mitochondrial Quality by Repairing or Eliminating Unhealthy Mitochondria , 2011, PloS one.

[81]  D. Birnbaum,et al.  Distinct roles of BARD1 isoforms in mitosis: full-length BARD1 mediates Aurora B degradation, cancer-associated BARD1beta scaffolds Aurora B and BRCA2. , 2009, Cancer research.

[82]  I. Ellis,et al.  Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes , 2009, Clinical Cancer Research.

[83]  T. Halazonetis,et al.  Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.

[84]  Mong-Hong Lee,et al.  Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer , 2010, Molecular Cancer.

[85]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[86]  B. A. Hocevar,et al.  Progression and treatment of HER2-positive breast cancer , 2010, Cancer Chemotherapy and Pharmacology.

[87]  Oliver Gautschi,et al.  Aurora Kinases as Anticancer Drug Targets , 2008, Clinical Cancer Research.

[88]  Mark D. Robinson,et al.  Moderated statistical tests for assessing differences in tag abundance , 2007, Bioinform..